A promising and clinically relevant finding was that reducing BRG1 expression sensitised both GICs and differentiated GBM tumour cells to the chemotherapeutic agent TMZ, likely due to the role BRG1 has in promoting DNA repair [61, 64]. The gene discussed is SMARCA4; the disease is neoplasm.